Clinical variables associated with pain, function, and health status. For all analyses the reference JIA category is oligoarticular-persistent JIA. Significant predictors in univariate analysis (p < 0.05) were included in initial multivariable models. The final multivariable models were built using a backward elimination, eliminating attributes with p > 0.2 when the full and nested models were compared. Only results for variables included in the final models are listed in the multivariable analyses columns. For binary variables, regression coefficients of 0.2, 0.5, and 0.8 are considered small, medium, and large associations, respectively20,29. For continuous predictors, regression coefficients of 0.1, 0.3, and 0.5 are considered small, medium, and large associations20,29.
| Pain Coefficient (95% CI) | Function Coefficient (95% CI) | Health Status Coefficient (95% CI) | ||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |
| ERA | 1.53 (1.17, 1.90)*** | 0.68 (0.21, 1.15)** | 0.18 (0.11, 0.25)*** | 0.09 (−0.01, 0.19) | 0.93 (0.66, 1.19)*** | 0.41 (0.02, 0.79)* |
| Undifferentiated | 0.75 (0.02, 1.49)* | 0.06 (−0.89, 1.02) | 0.18 (0.04, 0.32)* | 0.09 (−0.10, 0.28) | 0.35 (−0.17, 0.87) | 0.24 (−0.48, 0.96) |
| Polyarticular RF+ | 1.13 (0.71, 1.55)*** | 0.11 (−0.38, 0.59) | 0.24 (0.16, 0.32)*** | 0.00 (−0.12, 0.11) | 0.99 (0.69, 1.29)*** | 0.13 (−0.27, 0.54) |
| Psoriatic | 0.51 (0.06, 0.95)* | 0.42 (−0.14, 0.98) | 0.10 (0.01, 0.19)* | 0.05 (−0.07, 0.17) | 0.50 (0.19, 0.82)** | 0.10 (−0.35, 0.55) |
| Polyarticular RF– | 0.66 (0.39, 0.93)*** | −0.02 (−0.35, 0.30) | 0.21 (0.15, 0.26)*** | 0.02 (−0.08, 0.11) | 0.61 (0.42, 0.80)*** | 0.24 (−0.02, 0.51) |
| Systemic | 0.54 (0.15, 0.93)** | 0.11 (−0.30, 0.53) | 0.17 (0.10, 0.25)*** | 0.03 (−0.06, 0.13) | 0.72 (0.44, 1.00)*** | 0.46 (0.12, 0.80)** |
| Oligoarticular-extended | 0.27 (−0.13, 0.67) | 0.15 (−0.28, 0.59) | 0.13 (0.05, 0.21)** | 0.04 (−0.06, 0.15) | 0.21 (−0.07, 0.50) | 0.12 (−0.22, 0.47) |
| Older age (each additional yr) | 0.10 (0.08, 0.12)*** | 0.04 (0.02, 0.07)*** | 0.01 (−0.00, 0.01) | — | 0.07 (0.05, 0.08)*** | 0.05 (0.03, 0.07)*** |
| Symptom duration | 0.03 (0.01, 0.06)** | — | −0.01 (−0.01, 0.00) | — | 0.02 (0.00, 0.04) | — |
| Sex | 0.05 (−0.18, 0.28) | — | 0.04 (−0.00, 0.09) | — | 0.09 (−0.07, 0.25) | — |
| Active joint count | 0.18 (0.15, 0.20)*** | 0.11 (0.08, 0.14)*** | 0.04 (0.04, 0.05)*** | 0.03 (0.03, 0.04)*** | 0.11 (0.09, 0.13)*** | 0.07 (0.05, 0.10)*** |
| ≥ 5 joints ever affected | 0.41 (0.20, 0.62)*** | — | 0.17 (0.13, 0.21)*** | 0.06 (−0.01, 0.14) | 0.48 (0.33, 0.63)*** | — |
| Imaging evidence of joint damage | 0.23 (−0.03, 0.49) | — | 0.06 (0.01, 0.11)* | — | 0.45 (0.27, 0.63)*** | — |
| NSAID | 1.63 (1.44, 1.83)*** | 1.28 (1.04, 1.51)*** | 0.24 (0.20, 0.28)*** | 0.17 (0.13, 0.22)*** | 0.81 (0.66, 0.95)*** | 0.71 (0.52, 0.90)*** |
| DMARD | 0.03 (−0.17, 0.24) | — | 0.06 (0.02, 0.10)** | 0.09 (0.04, 0.14)*** | 0.30 (0.15, 0.44)*** | 0.45 (0.25, 0.65)*** |
| Biologics | 0.23 (0.02, 0.44)* | 0.39 (0.15, 0.64)** | 0.08 (0.04, 0.12)*** | 0.22 (0.15, 0.30)*** | 0.48 (0.33, 0.63)*** | 0.70 (0.39, 1.01)*** |
| Corticosteroids | 1.71 (1.35, 2.08)*** | 0.94 (0.57, 1.31)*** | 0.40 (0.33, 0.48)*** | 0.03 (−0.01, 0.08) | 1.23 (0.94, 1.51)*** | 0.14 (−0.05, 0.33) |
| Insured | −0.29 (−1.11, 0.53) | — | −0.06 (−0.23, 0.10) | — | 0.01 (−0.57, 0.60) | — |
| Uveitis | ||||||
| Current | — | — | — | — | 0.01 (−0.34, 0.37) | 0.53 (0.09, 0.97)* |
| Past | — | — | — | — | −0.44 (−0.72, −0.15)** | −0.09 (−0.44, 0.27) |